Alumis (ALMS) vs Monte Rosa Therapeutics (GLUE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Alumis (ALMS) has outperformed Monte Rosa Therapeutics (GLUE) over the past year, gaining 57.3% versus a gain of 33.9%. Alumis is the larger company by market cap ($926.8 million vs $878.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALMS | GLUE |
|---|---|---|
| Share price | $7.16 | $10.30 |
| Market cap | $926.76M | $878.73M |
| 1-day change | +2.73% | -0.19% |
| YTD return | -28.59% | -34.18% |
| 1-year return | +57.34% | +33.85% |
| 5-year return | — | -51.32% |
| EPS (TTM) | $-3.86 | $-1.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.35 | $25.77 |
| 52-week low | $4.28 | $8.53 |
| Distance from 52-week high | -77.16% | -60.03% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +348.74% | +171.84% |
| Average volume | 2.44M | 1.33M |
| Shares outstanding | 129.44M | 85.31M |
| Employees | 237 | 173 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALMS has outperformed GLUE by 23.5 percentage points over the past year.
About Alumis
ALMS stock →Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 237 employees
About Monte Rosa Therapeutics
GLUE stock →Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 173 employees
ALMS vs GLUE FAQ
Which is bigger, Alumis or Monte Rosa Therapeutics?
Alumis (ALMS) is larger, with a market capitalization of $926.76M compared with $878.73M for Monte Rosa Therapeutics (GLUE).
Which stock has performed better over the past year, ALMS or GLUE?
ALMS returned +57.34% over the past 12 months, compared with +33.85% for GLUE (price return, excluding dividends). Past performance does not predict future results.
Are Alumis and Monte Rosa Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Alumis and Biotechnology: Biological Products (No Diagnostic Substances) for Monte Rosa Therapeutics.